Loading...
XSWXBANB
Market cap4.79bUSD
Dec 20, Last price  
57.10CHF
1D
-6.62%
1Q
-19.92%
Jan 2017
-36.77%
Name

Bachem Holding AG

Chart & Performance

D1W1MN
XSWX:BANB chart
P/E
38.27
P/S
7.42
EPS
1.49
Div Yield, %
1.31%
Shrs. gr., 5y
1.92%
Rev. gr., 5y
15.37%
Revenues
577m
+8.57%
147,828,000153,656,000171,754,000198,318,000194,997,000181,848,000152,884,000145,808,000157,298,000170,685,000183,937,000208,604,000236,478,000261,612,000282,500,000313,715,000401,995,000503,234,000531,741,000577,316,000
Net income
112m
+11.10%
32,305,00039,232,00046,649,00063,927,00058,709,00046,057,00028,297,0009,409,00015,300,00023,604,00029,065,00031,838,00041,205,00041,770,00046,644,00054,164,00078,062,000114,682,000100,684,000111,859,000
CFO
250m
+169.86%
49,818,00027,423,00040,150,00078,070,00039,277,00042,847,00038,110,00024,609,00036,871,00049,230,00047,218,00061,434,00040,409,00036,479,00025,776,00063,648,000114,628,00097,163,00092,589,000249,864,000
Dividend
Apr 26, 20240.8 CHF/sh
Earnings
Feb 27, 2025

Profile

Bachem Holding AG provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. The company engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). It also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, and supply and vertical integration services. The company was founded in 1971 and is headquartered in Bubendorf, Switzerland.
URL
https://www.bachem.com/
IPO date
Jun 29, 2001
Employees
1,926
Domiciled in
CH
Incorporated in
CH

Valuation

Title
CHF in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
577,316
8.57%
531,741
5.66%
503,234
25.18%
Cost of revenue
448,754
405,428
375,191
Unusual Expense (Income)
NOPBT
128,562
126,313
128,043
NOPBT Margin
22.27%
23.75%
25.44%
Operating Taxes
12,349
11,390
16,704
Tax Rate
9.61%
9.02%
13.05%
NOPAT
116,213
114,923
111,339
Net income
111,859
11.10%
100,684
-12.21%
114,682
46.91%
Dividends
(56,236)
(51,620)
(20,490)
Dividend yield
1.16%
0.88%
0.04%
Proceeds from repurchase of equity
105,282
33,944
570,713
BB yield
-2.17%
-0.58%
-1.13%
Debt
Debt current
339
20,364
Long-term debt
436
704
998
Deferred revenue
(49,076)
Other long-term liabilities
145,561
49,076
(1)
Net debt
(298,091)
(267,384)
(420,994)
Cash flow
Cash from operating activities
249,864
92,589
97,163
CAPEX
(268,402)
(142,344)
(116,826)
Cash from investing activities
(170,807)
(63,166)
(469,130)
Cash from financing activities
48,689
(86,932)
437,581
FCF
(162,873)
(89,582)
(32,309)
Balance
Cash
298,527
268,427
442,356
Long term investments
Excess cash
269,661
241,840
417,194
Stockholders' equity
658,120
587,733
512,570
Invested Capital
1,196,641
917,378
722,457
ROIC
10.99%
14.02%
17.15%
ROCE
8.47%
10.45%
10.83%
EV
Common stock shares outstanding
74,688
73,735
70,847
Price
65.00
-18.60%
79.85
-88.85%
716.00
81.04%
Market cap
4,854,750
-17.54%
5,887,709
-88.39%
50,726,269
83.26%
EV
4,556,659
5,620,325
50,305,275
EBITDA
165,918
159,631
156,466
EV/EBITDA
27.46
35.21
321.51
Interest
367
719
798
Interest/NOPBT
0.29%
0.57%
0.62%